The incidence of acute exacerbation (AEx) of idiopathic interstitial pneumonias related to each first-line chemotherapy regimen
| Regimen | Patients | AEx |
| Carboplatin+paclitaxel | 140 (35.4%) | 12 (8.6%) |
| Carboplatin+etoposide | 82 (20.7%) | 3 (3.7%) |
| Cisplatin+etoposide | 38 (9.6%) | 4 (10.5%) |
| Vinorelbine | 30 (7.6%) | 8 (26.7%) |
| Cisplatin+UFT | 17 (4.3%) | 5 (29.4%) |
| Carboplatin+vinorelbine | 10 (2.5%) | 0 (0%) |
| Cisplatin+vinorelbine | 9 (2.3%) | 2 (22.2%) |
| Docetaxel | 7 (1.8%) | 1 (14.3%) |
| Carboplatin+docetaxel | 6 (1.5%) | 4 (66.7%) |
| Cisplatin+docetaxel | 6 (1.5%) | 1 (1.7%) |
| Gefitinib | 6 (1.5%) | 5 (83.3%) |
| Others | 51 | 10 (19.6%) |
| Total | 396 | 52 (13.1%) |
UFT: tegafur-uracil.